文献速递泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗

ALERT-B问卷:前列腺癌放疗后消化道晚期效应的筛查工具

The ALERT-B questionnaire: A screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-02-04

本研究追踪ALERT-B问卷阳性的前列腺癌放疗患者,检验该问卷识别后续胃肠并发症的能力,并对基线数据进行ROC分析。结果显示,ALERT-B阳性患者中分别有84.4%和95.7%在治疗后6个月和12个月确诊并发症;基线ALERT-B评分对GSRS腹泻子量表和EPIC肠道子量表所界定副作用水平的AUC分别为0.867和0.765。

要点

  • ALERT-B问卷含4个肠道症状条目,任一条目答「是」即转诊消化科。
  • ALERT-B阳性患者治疗后6个月和12个月并发症确诊率分别为84.4%和95.7%。
  • 基线ALERT-B评分对GSRS腹泻子量表相关副作用水平的AUC为0.867(95%CI 0.795–0.926)。

核心结论

  • ALERT-B是识别前列腺癌放疗后胃肠并发症的简便有效筛查工具。

研究设计与样本

  • 本研究追踪ALERT-B问卷阳性的前列腺癌放疗患者,并对基线数据进行受试者工作特征曲线(ROC)分析。
  • 以GSRS子量表和EPIC-26问卷为参照,评估ALERT-B总分的判别能力。

主要发现

  • ALERT-B问卷识别的患者中,84.4%在治疗后6个月、95.7%在治疗后12个月确诊并发症。
  • 基线ALERT-B评分对GSRS腹泻子量表界定的临床相关副作用水平AUC=0.867(95%CI 0.795–0.926)。
  • 基线ALERT-B评分对EPIC肠道子量表最小重要副作用水平AUC=0.765(95%CI 0.617–0.913)。

关键数值与推荐

  • ALERT-B问卷由4个肠道症状相关条目组成。
  • 任一问题回答「是」即转诊至消化科。
  • GSRS腹泻子量表相关副作用水平AUC=0.867(95%CI 0.795–0.926)。
  • EPIC肠道子量表最小重要副作用水平AUC=0.765(95%CI 0.617–0.913)。

临床怎么用

  • 前列腺癌放疗后可用ALERT-B问卷筛查肠道晚期效应,阳性者及时转诊消化科。
  • 问卷条目少、操作简便,适合作为常规随访中的初筛工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an increasing need to measure treatment-related side effects in normal tissues following cancer therapy. The ALERT-B (Assessment of Late Effects of RadioTherapy - Bowel) questionnaire is a screening tool that is composed of four items related specifically to bowel symptoms. Those patients that respond with a "yes" to any of these items are referred on to gastroenterologist in order to improve the long-term consequences of these side effects of radiological treatment. Here we wish to test the ability of this questionnaire to identify these subsequent gastroenterological complications by tracking prostate cancer patients that were positive with respect to ALERT-B. We also carry out receiver-operator curve (ROC) analysis for baseline data for an overall ALERT-B questionnaire score with respect to subscale data for the Gastrointestinal Symptom Rating Scale (GSRS) and the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire. 84.4% and 95.7% of patients identified by the ALERT-B questionnaire demonstrated complications diagnosed at 6 and 12 months post-treatment, respectively. ROC curve analysis of baseline data showed that ALERT-B detected clinically relevant levels of side effects established at baseline by the GSRS diarrhoea subscale (AUC = 0.867, 95% CI = 0.795 to 0.926) and at the minimally important level of side effects for the EPIC bowel subscale (AUC = 0.765, 95% CI = 0.617 to 0.913). These results show that ALERT-B provides a simple and effective screening tool for identifying gastroenterological complications after treatment for prostate cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Farnell DJJ, Staffurth J, Sivell S, et al. The ALERT-B questionnaire: A screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Clin Transl Radiat Oncol. 2020. PMID: 32072031. doi:10.1016/j.ctro.2020.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。